Alefacept
CD2-directed LFA-3/Fc Fusion Protein — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Also known as: amevive, BG9273, BG9712, LFA3TIP
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Alefacept is a drug in the CD2-directed LFA-3/Fc Fusion Protein class catalogued in DrugCentral. It was first approved by the FDA in 2003. Its mechanism of action is classified as CD2-directed Antibody Interactions. DrugCentral lists 1 molecular target, including CD2. Recorded indications include Plaque psoriasis.
- Drug class: CD2-directed LFA-3/Fc Fusion Protein.
- Mechanism of action: CD2-directed Antibody Interactions.
- Molecular targets: CD2 (1 listed in DrugCentral).
- Indications: Plaque psoriasis.
- ATC code: L04AA15 (Selective immunosuppressants).
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Plaque psoriasis
Mechanism & targets
| Mechanism of action (MoA) | CD2-directed Antibody Interactions |
|---|---|
| Established pharmacologic class | CD2-directed LFA-3/Fc Fusion Protein |
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| T-cell surface antigen CD2 | CD2 | inhibitor | — |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2003-01-30 | FDA | — | ASTELLAS |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
L04AA15 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Selective immunosuppressants |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Neurologic neglect syndrome | 759.9 |
| Carotid artery thrombosis | 758.4 |
| Adjustment disorder | 728.9 |
| Personality disorder | 694.7 |
| Affect lability | 617.7 |
| Skin haemorrhage | 613.5 |
| Sensory loss | 607.4 |
| Hemiplegia | 596.0 |
| Motor dysfunction | 580.2 |
| Sinus congestion | 578.1 |
| Respiratory tract congestion | 576.6 |
| Arterial occlusive disease | 575.7 |
Chemical structure
| Molecular formula | — |
|---|---|
| Molecular weight | — |
| CAS number | — |
| InChIKey | — |
| PubChem CID | — |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Alefacept used for?
DrugCentral lists the following indications for Alefacept: Plaque psoriasis.
How does Alefacept work?
Alefacept is classified as CD2-directed Antibody Interactions; its molecular targets in DrugCentral include CD2 (inhibitor).
When was Alefacept first approved?
Alefacept was first approved by the FDA in 2003.
What drug class does Alefacept belong to?
Alefacept is in the CD2-directed LFA-3/Fc Fusion Protein class.
Browse: all drugs starting with A · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5088 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1201571 — compound record and bioactivity
- DrugBank DB00092 — drug record
- FDA UNII ELK3V90G6C — substance identity
- DailyMed: FDA labels for Alefacept — current prescribing information (label search)
- UniProt P06729 (CD2) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.